Human high molecular weight-B cell growth factor (HMW-BCGF) (60 kD) stimulates activated normal B cells, B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, hairy cell leukemia (HCL) cells, prolymphocytic leukemia (PLL) cells, and chronic lymphocytic leukemia (CLL) cells. The expression of human high molecular weight B cell growth factor (HMW-BCGF) receptors (R) on clonal populations of leukemic B cells in CLL was studied by ligand binding assays using 125I-labeled HMW-BCGF as well as by immunofluorescence/flow cytometry and Scatchard analyses using an anti-HMW-BCGF R monoclonal antibody (MAb), designated BA-5. There was a high correlation between HMW-BCGF R expression and responsiveness to HMW-BCGF. 60% of CLL cases constitutively expressed HMW-BCGF R and showed a marked proliferative response to HMW-BCGF in [3H]TdR incorporation assays as well as colony assays. Similarly, HCL cells, PLL cells, and activated normal B cells expressed functional HMW-BCGF R, as determined by ligand binding assays using 125I-HMW-BCGF, [3H]TdR incorporation assays, and reactivity with BA-5 MAb. Scatchard analyses indicated the existence of approximately 3,000 HMW-BCGF R/cell on HMW-BCGF responsive CLL cells with an apparent Ka value of 4.6 X 10(7) M-1. The concentrations of HMW-BCGF required for maximum stimulation of CLL cells were two to three orders of magnitude lower than those needed for half maximal receptor occupancy, indicating that only a small fraction of HMW-BCGF R need to be […] Research Article
Introduction
Human B lymphocyte development is a multistep maturation process that involves activation, proliferation, and differentiation accompanied by a coordinated acquisition and loss of B lineage differentiation/activation antigens and surface growth factor (GF)' R. Uncoupling of proliferation and differentiation may occur at multiple stages of B cell ontogeny and is thought to be the underlying mechanism for the stabilization and expansion of transitory cellular phenotypes leading to B lineage lymphoid malignancies (1) . Several candidate hematopoietic GF have been described that may play a key role in proliferation and differentiation of human B lineage cells (2-1 1). Current areas of intense investigation include analysis of the structural and functional features of these biomodulatory molecules, identification and characterization of their R, and elucidation oftheir roles in human B lymphocyte development as well as in leukemogenesis and disease progression of B lineage lymphoid malignancies . One ofthese factors is a 60-kD high molecular weight-B cell growth factor (HMW-BCGF), which is produced by normal T cells, T cell clones, and T lineage as well as B lineage lymphoma cell lines and provides a potent progression/proliferation signal for activated B cells (7, 8) . The availability of highly purified HMW-BCGF (8) and a monoclonal antibody reactive with the receptor for HMW-BCGF (17) permit detailed analyses of HMW-BCGF R expression, structure, and function. Resting normal tonsillary or peripheral blood B lymphocytes express only 50-350 HMW-BCGF R/cell and do not show any significant proliferative response to HMW-BCGF (17) . By comparison, activated normal tonsillary or peripheral blood B-lymphocytes express 1-5 X 104 HMW-BCGF R/cell and show a marked proliferative response to HMW-BCGF (17) . 251I-HMW-BCGF crosslinked to its binding site on Sac-activated B-lymphocytes produces a 150-kD R-protein complex recognized by both BA-5 MAb reactive with the 90-kD ligand binding site of the receptor as well as by BCGF/1/C2 MAb specifically reactive with HMW-BCGF (17) .
Our recent studies demonstrated that leukemic BCPs from BCP-ALL patients, but not normal fetal liver or fetal bone marrow BCPs, constitutively express functional HMW-BCGF R and proliferate in response to HMW-BCGF in the absence of comitogens or accessory cell populations (10) (11) (12) , providing suggestive evidence that HMW-BCGF may play an important regulatory role in clonal expansion of neoplastic B cell precursor populations in "immature" B cell malignancies (12). The bioactivities and growth regulatory role of 60 kD 11MW-BCGF in "mature" B cell malignancies, such as CLL, has not as yet been analyzed.
The purpose of the present study was the detection and characterization of HMW-BCGF R in CLL. We used 1251 labeled purified HMW 
Methods
Reagents. MAbs 35.1 (anti-CD2), OKT3 (anti-CD3), TIOl (anti-CD5), BA-3/24.1 (anti-CD10), B43 (anti-CD19), Bi (anti-CD20), G28-7/Leul4 (anti-CD22), BA-I (anti-CD24), G28.8 (anti-Bgp95), G28-5 (anti-CD40), BA-5 (anti-HMW-BCGF R), and LeuM-5 (antiCDlIc) were used to study the surface antigen profiles of leukemic cells by indirect immunofluorescence, as previously described (13) (14) (15) (16) .
In some experiments, cells were two-color stained for HMW-BCGF R and CD 19 using BA-5-FITC and B43-PE, as previously described (10, 13) . The presence of surface and cytoplasmic immunoglobulin (Ig) was studied by direct immunofluorescence using rabbit antisera specific to human IgM, IgD, IgA, IgG heavy chains, and kappa and lambda light chains. Biochemically purified HMW-BCGF and LMW-BCGF and '25I-HMW-BCGF (1 X I 0'7 cpm/mol) were prepared as previously reported (6, 8, 12) . Purification and 1251 labeling ofBA-5 MAb has been previously described in detail (17) . The specific activity of '251-BA-5 was 1.5 X 1017 cpm/mol (= 1 X 106 cpm/jug). The purity of '25I-HMW-BCGF and '251-BA-5 was confirmed by an analytical SDS-PAGE and autoradiography which revealed single bands ( Fig. 1) : In brief, aliquots of 1251 labeled HMW-BCGF (-200,000 cpm) and BA-5 (-100,000 cpm) were boiled in Tris buffer containing SDS, glycerol, and bromophenol blue tracking dye, and run on a 7.5% mini-gel (Mini-Protean II; Bio-Rad Laboratories Richmond, CA), according to the method of Laemmli and as previously reported (33, 34) . The gel was dried and exposed at -70'C for 30 h using Kodak XAR-5 film and Dupont Quanta II Cronex enhancer screens, as previously described (33, 34) . The positions of the prestained molecular weight standards, including f3-galactosidase (116 kD), phosphorylase B (95.5 kD), and glutamate dehydrogenase (55 kD) are indicated on the left (Fig. 1) . The autoradiograms were scanned using DU-62 Spectrophotometer equipped with a gel scanning attachment (Beckman Instruments, Inc., Fullerton, CA (7, 8, 12, 17) . The specific binding of '251-HMW-BCGF (1 X 10'7 cpm/mol) to plasma membrane receptors on fresh CLL cells was evaluated in standard ligand binding assays in the presence and absence of 50-fold excess cold HMW-BCGF, as previously described in detail (12, 17) . Equilibrium binding assays and Scatchard analyses of HMW-BCGF R expression on CLL cells were performed using 125i labeled BA-5 MAb as follows: Cells were washed three times in cold alpha-MEM supplemented with 10% calf bovine serum, 10 mM Hepes buffer, 1% penicillin/streptomycin, and 0.1% sodium azide (binding medium, pH 7.4). After the final wash, the cells were resuspended in freshly prepared cold binding medium, and maintained at 4°C for 60 min before use to halt the internalization of cell surface receptors for HMW-BCGF. All subsequent steps were performed at 4°C. 5 X 10-10-l X l0-7 M '251-BA-5 (1.5 X 1017 cpm/mol) with or without 100-fold molar excess of unlabeled BA-5 MAb was added in 100 ML binding medium to 10 X 106 CLL cells in 1 50-,l duplicate samples so that the final assay volume in each replicate sample was 250 /l. The samples were gently agitated every 30 min for 4 h to prevent the cells from settling and left overnight at 4°C. At the end of the 24-h incubation period, the cell preparations were diluted 1:1 with calf bovine serum and centrifuged at 4°C through a 2-ml calf bovine serum cushion to separate bound and free '25I-BA-5, and the radioactivity associated with the cell pellet (cpm) was determined for a 2-min period by liquid scintillation counting. The radioactivity bound in the presence of excess cold BA-5 was subtracted from the total binding to yield the specific binding. Scatchard plot analysis of the equilibrium binding data was performed was described previously for characterization of IL-1, IL-3, and CD 19 receptors on leukemic BCPs, and HMW-BCGF R on activated normal B cells (13, 33, 34) . Affinity cross-linking was performed as described by Lee and Conrad (18) for cross-linking IgE to its Fc receptor on B lymphocytes. HMW-BCGF for these studies was
'a purified to homogeneity by a three-step procedure which consisted of (1) negative immunoabsorption of PHA stimulated Namalwa super- (10, 12, 13) . BA-5+ FACS sorted fractions were > 99% pure as determined by reanalysis on FACS 440. The proliferative responses ofthese FACS sorted CLL cell populations to HMW-BCGF were determined in a colony assay system, as described hereinafter.
CLL colony assay system. CLL cells were assayed for colony formation in the presence of HMW-BCGF or LMW-BCGF using a colony assay system previously described for cloning leukemic BCPs (10-15, 33, 34) . Cells were suspended in alpha-MEM supplemented with 0.9% methylcellulose, 30% calf bovine serum, indicated concentrations of HMW-BCGF or LMW-BCGF, or no added exogenous growth factor. In some experiments, anti-Tac (anti-IL-2 R) or BA-5 (anti-HMW-BCGF R) MAbs (25 ,g/ml) were also added to the cultures. Duplicate 1 ml samples containing 3 X 105 CLL cells were cultured in 35 mm Petri dishes for 7 d at 37°C in a humidified 5% atmosphere. On day 7, CLL colonies containing > 20 cells were counted on a grid using an inverted phase microscope with high optical resolution. Subsequently, immunological analyses of colony cells were performed as described (10) (11) (12) (13) (14) (15) Fig. 2) . In contrast to HMW-BCGF, LMW-BCGF stimulated CLL colony formation only in one (CLL 7) of 9 cases analyzed. In three CLL cases with spontaneous colony formation, LMW-BCGF was inhibitory and in the remaining six CLL cases it failed to stimulate colony formation (Table III) . We also used virtually pure populations of BA-5+ FACS sorted CLL cells from two HMW-BCGF responsive cases (CLLs 5 and 7) to preclude accessory cells from affecting the HMW-BCGF responses of CLL cells (Table III) . The light scattering contour plots, BA-5 reactivity, and the windows used for sorting are shown in Fig. 3 (Tables II-IV) . In contrast, no stimulation was observed in four cases that showed no significant '25I-HMW-BCGF binding (Tables II-IV fmol/ 106 cells) (= 13,274±7,269 molecules/cell) of '251I-HMW-BCGF were specifically bound to HCL cells. The percent BA-5 positivity in these three cases ranged from 25% to 65% (Table   a) .:. Table II (Tables II, IV) . Resting T cells did not exhibit any significant specific '25I-HMW-BCGF binding (Table IV) . Table V (Table V) . In contrast to BA-5, anti-Tac (anti-IL-2 R) MAb Tables II and III) . Thus, the concentration of HMW-BCGF required for half-maximal receptor occupancy appears to be 300-600-fold higher than the concentrations of HMW-BCGF required to elicit maximum stimulation of CLL cells, indicating that only a small fraction of HMW-BCGF R need to be occupied to stimulate CLL cells. This discrepancy between the ligand concentration required for half-maximal receptor occupancy vs the ligand concentration required for maximum stimulation is a common feature of many growth factor receptors on human hematopoietic cells (33, 34) . (Fig. 6, lanes 6  and 8) . Subtracting the molecular weight of the crosslinked HMW-BCGF (60 kD), this suggests that the HMW-BCGF R is (Fig. 6, lanes 3, 5, 8 ).
Discussion
In this study, we elucidated the functional properties and structural nature of plasma membrane R for human HMW-BCGF on malignant B-lymphocytes from CLL patients using 1251I labeled purified HMW-BCGF, BA- (8, 17) . The constitutive expression of functional HMW-BCGF R on CLL cells (1) suggests that HMW-BCGF may be involved in the clonal expansion of malignantly transformed B lymphocytes and (2) recommends future long-term studies of its role in leukemogenesis and disease progression in CLL. Our observation that not all CLLs expressed functional HMW-BCGF R provides suggestive evidence that CLL may be a biologically heterogeneous group of diseases, which supports and extends the findings of Karray et al. (27) , and Hivroz et al. (28) . Whether or not biologically and prognostically distinct subgroups of patients can be identified based on HMW-BCGF R expression will be the subject of separate long-term studies. B lineage CLL represents clonal expansions of relatively mature B lymphocyte populations (1, 19) . The putative normal counterparts of CLL cells are thought to be CD5/T 1 'sIg'B lymphocytes found in normal adult as well as fetal lymph nodes (1, 20, 21) . Freshly isolated B lineage CLL cells have been reported to have a very low proliferative activity (19) with more than 99% of cells in the Go phase of the cell cycle and < 0.1% in the S-phase (22) and are unresponsive to (10) (11) (12) (13) (14) (15) . We have used this assay system to study the growth factor requirements and surface differentiation antigen profiles of normal and leukemic BCPs (10) (11) (12) (13) (14) (15) . Our comparative analyses of the immunobiologic features of leukemic BCPs and their putative normal counterparts in normal fetal bone marrow/liver revealed significant differences between normal and leukemic BCPs (10) , emphasizing the potential value of this colony assay system for a better understanding ofthe basic biology of human B lineage lymphoid malignancies. The present study demonstrates that, when HMW-BCGF is used for stimulation, this assay system allows reproducible proliferation and colony formation of fresh leukemic B cells from CLL patients, as well. Experimental data produced in this model system will likely provide valuable information about the immunobiologic features of leukemic CLL B cells and their putative normal counterparts in human lymphoid tissues. The availability of a reproducible CLL colony assay should promote future analyses of GF interactions at the level of clonogenic CLL cells. A major finding of potential clinical significance presented in this paper is that BA-5 (anti-HMW-BCGF R) MAb inhibited HMW-BCGF induced CLL cell proliferation. The opportunity is thus provided for using BA-5 MAb to disrupt HMW-BCGF/HMW-BCGF R interactions in malignant B lymphocyte populations which may ultimately lead to a more effective treatment strategy for high risk CLL.
